Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Lilly's daily obesity pill, orforglipron, shows positive results in late-stage trial, with patients losing nearly 12% of body ...

Investing.com -- Viking Therapeutics (NASDAQ: VKTX) stock rose 11% Thursday after Eli Lilly’s (NYSE: LLY) data on its oral ...

By Jesus Calero and Elviira Luoma (Reuters) -Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli ...

Shock’ as study reveals how weight-loss pill stacks up against injections - Shares in a pharmaceutical company plummeted ...

Note that some links may require registration or subscription. Experiments showed that the recommended 6 feet of social ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...